INmune Bio Inc (NASDAQ:INMB) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $11.00 and last traded at $10.39, with a volume of 16184 shares changing hands. The stock had previously closed at $10.36.
Separately, Maxim Group began coverage on shares of INmune Bio in a research report on Tuesday, March 19th. They set a “buy” rating and a $13.00 target price on the stock.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4301290/inmune-bio-inmb-hits-new-12-month-high-at-11-00.html.
INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.
Featured Story: Why does the United States have a lingering trade deficit?
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.